fullscreen

eFinder

eFinder

Home › Indian Equity Market Volatility › Article

Singapore's Temasek is on a hot streak in India as three bets surge after IPOs

Cnbc · 🇮🇳 public India · · 465 words · By Priyanka Salve
Indian Equity Market Volatility Foreign Direct Investment in India Temasek Holdings Investment Strategy
headphones Listen to the eFinder podcast briefing
Generate a natural audio summary of this story
Daily briefing

What to know about Indian Equity Market Volatility

Singapore state investor Temasek Holdings is on a hot streak in India, where three of its portfolio companies have gained more than 30% after market debuts this week.

Claims checked 11
Techniques found 1
Topics 3

Coverage spectrum

Coverage gap: Low Left coverage
Left0%
Center80%
Right20%

5 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Singapore state investor Temasek Holdings is on a hot streak in India, where three of its portfolio companies have gained more than 30% after market debuts this week.

Why it matters

On Wednesday, shares of logistics company Shiprocket listed at a 35% premium and ended the day at 143 rupees ($1.50), nearly 50% above the initial public offering price.

Common ground

The IPO was oversubscribed nearly 100 times, owing to strong demand from both institutional and retail investors.

Perspective signals

The tension in the story is sharpened by Loaded Language: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

open_in_new Read the original article: https://www.cnbc.com/2026/08/20/singapore-temasek-india-foreign-shiprocket-milky…

psychologyPropaganda Techniques Detected

eFinder identified 1 propaganda technique in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning
Loaded Language 70% confidence
Using words with strong emotional connotations to influence an audience.
Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.
Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 11 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

help Insufficient Evidence 4
info Single Source 3
check_circle Corroborated 2
report Misleading 1
schedule Pending 1
info
Claim 1: “the sovereign wealth fund has deployed nearly $9 billion in India in the last three years”
SINGLE SOURCE
Sources mention Temasek 'eyes up to 10 bn' or has invested '$37 billion over 20 years', but no source confirms the specific figure of 'nearly $9 billion in the last three years'.
travel_explore
web search NEUTRAL — temasek eyes up to 10 bn investment in india over three years.Temasek buys 41 per cent stake in India's Manipal Health for $2 bln. While Manipal did not specify the deal value, Temasek has paid about …
https://health.economictimes.indiatimes.com/tag/temasek
travel_explore
web search NEUTRAL — The investment company had the S$266 (US$ 197) billion net portfolio in 2014-15, with a top three investment exposure to Singapore (28 per cent), China (27 per cent) and Australia (9 per cent). India …
https://www.business-standard.com/article/finance/temasek-ho…
travel_explore
web search NEUTRAL — Temasek has invested nearly $37 billion in India over the past 20 years, with plans to significantly increase this amount.
https://en.channeliam.com/2024/10/04/temasek-holdings-invest…
info
Claim 2: “Dairy product maker Milky Mist, which listed on Tuesday, traded 40% above the IPO price on Wednesday”
SINGLE SOURCE
One web search result mentions Milky Mist listed and shares rose 40% post-IPO, but there is no independent corroboration from other sources regarding the specific Tuesday/Wednesday timeline.
help
Claim 3: “foreign investors, who sold nearly $19 billion of Indian equities last year and have been net sellers for most of this year, leading to outflows worth $24.7 billion through Aug. 19, according to data from NSDL”
INSUFFICIENT EVIDENCE
No evidence was found in the search results to corroborate or refute the NSDL data regarding foreign investor outflows.
check_circle
Claim 4: “The IPO [of Shiprocket] was oversubscribed nearly 100 times”
CORROBORATED
Multiple independent web sources confirm the IPO was oversubscribed nearly 100 times (specifically cited as 'nearly 100 times' and '99.38 times').
menu_book
wikipedia NEUTRAL — Arjun Sethi (born January 15, 1983) is an American internet entrepreneur, investor and executive. Currently a co-CEO of the cryptocurrency exchange Kraken, he is also chairman of Tribe Capital, a comp…
https://en.wikipedia.org/wiki/Arjun_Sethi_(entrepreneur)
travel_explore
web search NEUTRAL — We compete fiercely with Shiprocket. But today isnt the day to talk about competition - it’s the day to celebrate India’s largest e-commerce enabler having an amazing debut in the public markets Until…
https://www.linkedin.com/posts/abhiroopm_shiprockets-ipo-was…
travel_explore
web search NEUTRAL — Check Shiprocket IPO allotment status on KFin Technologies, BSE, and NSE.Demand was extremely strong across every category. The IPO was subscribed nearly 100 times overall, showing that investor deman…
https://www.indmoney.com/blog/ipo/shiprocket-ipo-allotment-s…
+ 1 more evidence source
report
Claim 5: “shares of logistics company Shiprocket listed at a 35% premium and ended the day at 143 rupees ($1.50), nearly 50% above the initial public offering price”
MISLEADING
While multiple sources corroborate that Shiprocket listed at a 35% premium (NSE) and around 33-35% (BSE), the claim that it ended the day at 143 rupees (~50% above IPO price) is not supported by the provided evidence. The evidence mentions listing prices of 131 and 129.50, but does not confirm a closing price of 143.
travel_explore
web search NEUTRAL — Shiprocket made a strong stock market debut on Wednesday, August 19, 2026, with its shares listing at a 35.05 premium on the NSE.Shiprocket IPO - Issue Details. Issue Type: Book Built Issue (Fresh Iss…
https://groww.in/blog/shiprocket-shares-list-at-premium
travel_explore
web search NEUTRAL — On the BSE, it is listed at ₹129.50 per share, up 33.51% from the issue price. Shiprocket share price: Here's how much investors made per lot. A lot consisted of 154 shares and cost ₹14,938.
https://upstox.com/news/market-news/ipo/shiprocket-shares-li…
travel_explore
web search NEUTRAL — Shiprocket makes a strong debut on the bourses, listing at a premium of 35% to the issue price at Rs 131 on the NSE. The stock has listed at a 34% premium on the BSE at Rs 129.50.
https://economictimes.indiatimes.com/markets/ipos/fpos/shipr…
schedule
Claim 6: “The Singaporean fund has a total India exposure of $42 billion, representing a "four-fold growth over the decade,"”
PENDING
This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.
help
Claim 7: “In a survey of fund managers published by BofA Global Research on Tuesday, India emerged as the least favored market in Asia”
INSUFFICIENT EVIDENCE
No evidence was found regarding a BofA Global Research survey identifying India as the least favored market in Asia.
help
Claim 8: “Molbio Diagnostics, which debuted on Monday, traded at a premium of 26% to its IPO price, after a drop on Wednesday”
INSUFFICIENT EVIDENCE
The claim states Molbio Diagnostics traded at a premium of 26%. However, three independent sources explicitly state it listed at a premium of 'over 21 per cent' or '21.44%', directly contradicting the 26% figure.
travel_explore
web search NEUTRAL — Molbio Diagnostics' initial public offering received 70.26 times subscription on the final day of bidding on Wednesday last week. PTI.New Delhi: Shares of Molbio Diagnostics Ltd on Monday listed with …
https://health.economictimes.indiatimes.com/news/diagnostics…
travel_explore
web search NEUTRAL — Molbio Diagnostics' initial public offering received 70.26 times subscription on the final day of bidding on Wednesday last week. The Rs 940-crore IPO had a price band of Rs 768-807 per share.
https://money.rediff.com/news/market/molbio-diagnostics-shar…
travel_explore
web search NEUTRAL — Molbio Diagnostics IPO Listing Day Highlights. Molbio Diagnostics made its stock market debut on Monday, August 17, 2026. The stock listed at ₹980 on both the NSE and BSE, a premium of 21.44% over the…
https://www.venturasecurities.com/blog/molbio-diagnostics-ip…
check_circle
Claim 9: “Temasek holds over a 5% stake in both these companies [Shiprocket and Milky Mist]”
CORROBORATED
Multiple sources confirm Temasek's stakes. One source explicitly states Temasek holds over 5% in both Shiprocket and Milky Mist; another specifies a 5.16% stake in Milky Mist.
travel_explore
web search NEUTRAL — Dairy firm Milky Mist also listed, with its shares rising 40% post-IPO. Molbio Diagnostics, which went public earlier, saw a 26% premium despite a recent price dip. Temasek holds over 5% in both Shipr…
https://www.gurufocus.com/news/9044952/temaseks-investments-…
travel_explore
web search NEUTRAL — Milky Mist had raised Rs 482 crore in pre-IPO funding for a 5.16% stake in April and May from Jongsong Investments, an indirect wholly-owned subsidiary of Temasek Holdings.
https://www.newindianexpress.com/business/2026/Aug/06/milky-…
travel_explore
web search NEUTRAL — Three Temasek-backed companies, Molbio Diagnostics, Milky Mist and Shiprocket, have recently listed, and the firm continues to hold stakes in all three. At their latest share prices, those holdings ar…
https://www.moneycontrol.com/news/business/startup/3-ipos-an…
help
Claim 10: “Temasek-owned Indian hospital chain Manipal Health, which listed in India earlier this month, is at a 25% premium to its IPO price”
INSUFFICIENT EVIDENCE
The claim states Manipal Health is at a 25% premium. However, evidence from a listing report states it made its debut with a '13% rally over its IPO price', contradicting the 25% claim.
travel_explore
web search NEUTRAL — Manipal Health Enterprises made a strong stock market debut with a 13% rally over its IPO price, adding about ₹10,000 crore to investor wealth in a single session.
https://www.fortuneindia.com/markets/ipo/manipal-healths-13-…
travel_explore
web search NEUTRAL — The IPO is likely to value the Ranjan Pai-founded firm at $8.0-8.5 billion, people aware of the matter told Mint. This means that the IPO of Manipal Health, which competes with Apollo Hospitals and As…
https://www.livemint.com/industry/manipal-health-sebi-nod-1-…
travel_explore
web search NEUTRAL — Six IPOs including Rentomojo, Karamtara Engineering, Steamhouse India, LCC Projects, ARCIL and Manipal Payment list today. Check listing prices, GMP and investor gains.
https://www.businesstoday.in/markets/stocks/story/6-ipo-list…
info
Claim 11: “Temasek owns an 8.74% stake in the company [Molbio Diagnostics], according to data on the BSE”
SINGLE SOURCE
Only one source mentions the specific 8.74% stake in Molbio Diagnostics. Other sources discuss Temasek's general involvement or talks to acquire a 15% stake, but do not confirm the 8.74% BSE data.
travel_explore
web search NEUTRAL — Three Temasek-backed companies, Molbio Diagnostics, Milky Mist and Shiprocket, have recently listed, and the firm continues to hold stakes in all three.Its 4.62 percent stake in Shiprocket is worth ar…
https://www.moneycontrol.com/news/business/startup/3-ipos-an…
travel_explore
web search NEUTRAL — The Singapore government’s investment fund Temasek Holdings is in advanced talks to acquire about 15% stake in Covid-19 test kits maker Molbio Diagnostics for ₹1,500-₹1,800 crore ($250 million), multi…
https://economictimes.indiatimes.com/industry/healthcare/bio…
travel_explore
web search NEUTRAL — Molbio Diagnostics Limited has fixed the price band for its Initial Public Offering (IPO) at ₹768 to ₹807 per equity share of face value Re 1. The ₹200-crore fresh issue along with an offer for sale (…
https://www.angelone.in/news/market-updates/molbio-diagnosti…
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.